June 23, 2023 3:22 am
This comes nearly a year after 70 children died in the Gambia allegedly after consuming contaminated syrups manufactured by Haryana-based Maiden pharmaceuticals.
March 04, 2023 12:31 am
Last year, 80 children were confirmed to have suffered from AKI in The Gambia between June and November. Of them, 70 died.
January 14, 2023 4:48 pm
The solvent, propylene glycol, is said to be the most likely source of the contaminants that have been reported in two Marion-made syrups — Ambronol and Dok-1 Max — by the Uzbek national quality control laboratory. The contaminants were identified by Uzbek authorities as ethylene glycol and di-ethylene glycol.
January 13, 2023 1:08 am
The Indian Express had reported that some of the “deviations” included specifications for conducting certain tests that were not followed, pressure differences between areas that weren't maintained, and some gauges used to record pressure differences that weren’t working.
December 29, 2022 11:25 am
In a statement, the Uzbekistan ministry said laboratory tests of the preparation found presence of the contaminant ethylene glycol. It said the medicine was consumed without prescription and in a higher dose by the children affected.
December 24, 2022 7:45 am
Report comes after Indian authority gave clean chit, said no causal link data shared
December 16, 2022 2:15 am
The WHO medical alert in October linked four syrups manufactured by Haryana-based Maiden Pharmaceuticals.
October 21, 2022 3:33 pm
Swaminathan was speaking to reporters on Thursday on the sidelines of the annual general meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) in Pune
October 16, 2022 10:23 pm
DGCI V G Somani said the manufacturing site has been inspected, test reports of sampled products from the laboratory are awaited and all the manufacturing activities of the manufacturer in question have been stopped.
October 13, 2022 7:50 am
Earlier in the day, the Haryana government ordered a “complete stop” on production by the company after finding violations of good manufacturing practices and deficiencies in documentation during four inspections by drug control officials.